European Police Systems

Disbound Original Held in Oak Street Library Facility.Includes bibliographical references (p. [407]-420) and index.Preservation photocopy.Mode of access: Internet

Dedication of the Palomar Observatory and the Hale Telescope

The dedication of the Palomar Observatory, if it were being held in England, would be accompanied by brilliant pageantry both of the state, with its knights, heralds, pursuivants, kings at arms, admirals and captains, and of the church with its bishops, priests and deacons, crucifiers and choirs; and I am sure that we feel the quality of religion in this ceremony. We would hear the choirs chanting in antiphony that great canticle which so delights the choir boys: Benedicite, omnia opera Domini

Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection: A case control study

Introduction: The use of anti-retroviral therapy (ART) has dramatically reduced HIV-1 associated morbidity and mortality. However, HIV-1 infected individuals have increased rates of morbidity and mortality compared to the non-HIV-1 infected population and this appears to be related to end-organ diseases collectively referred to as Serious Non-AIDS Events (SNAEs). Circulating miRNAs are reported as promising biomarkers for a number of human disease conditions including those that constitute SNAEs. Our study sought to investigate the potential of selected miRNAs in predicting mortality in HIV-1 infected ART treated individuals. Materials and Methods: A set of miRNAs was chosen based on published associations with human disease conditions that constitute SNAEs. This case: control study compared 126 cases (individuals who died whilst on therapy), and 247 matched controls (individuals who remained alive). Cases and controls were ART treated participants of two pivotal HIV-1 trials. The relative abundance of each miRNA in serum was measured, by RTqPCR. Associations with mortality (all-cause, cardiovascular and malignancy) were assessed by logistic regression analysis. Correlations between miRNAs and CD4+ T cell count, hs-CRP, IL-6 and D-dimer were also assessed. Results: None of the selected miRNAs was associated with all-cause, cardiovascular or malignancy mortality. The levels of three miRNAs (miRs -21, -122 and -200a) correlated with IL-6 while miR-21 also correlated with D-dimer. Additionally, the abundance of miRs -31, -150 and -223, correlated with baseline CD4+ T cell count while the same three miRNAs plus miR- 145 correlated with nadir CD4+ T cell count. Discussion: No associations with mortality were found with any circulating miRNA studied. These results cast doubt onto the effectiveness of circulating miRNA as early predictors of mortality or the major underlying diseases that contribute to mortality in participants treated for HIV-1 infection

Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study

Ristola M. on työryhmien DAD Study Grp ; Royal Free Hosp Clin Cohort ; INSIGHT Study Grp ; SMART Study Grp ; ESPRIT Study Grp jäsen.Background Chronic kidney disease (CKD) is a major health issue for HIV-positive individuals, associated with increased morbidity and mortality. Development and implementation of a risk score model for CKD would allow comparison of the risks and benefits of adding potentially nephrotoxic antiretrovirals to a treatment regimen and would identify those at greatest risk of CKD. The aims of this study were to develop a simple, externally validated, and widely applicable long-term risk score model for CKD in HIV-positive individuals that can guide decision making in clinical practice. Methods and Findings A total of 17,954 HIV-positive individuals from the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study with >= 3 estimated glomerular filtration rate (eGFR) values after 1 January 2004 were included. Baseline was defined as the first eGFR > 60 ml/min/1.73 m2 after 1 January 2004; individuals with exposure to tenofovir, atazanavir, atazanavir/ritonavir, lopinavir/ritonavir, other boosted protease inhibitors before baseline were excluded. CKD was defined as confirmed (>3 mo apart) eGFR In the D:A:D study, 641 individuals developed CKD during 103,185 person-years of follow-up (PYFU; incidence 6.2/1,000 PYFU, 95% CI 5.7-6.7; median follow-up 6.1 y, range 0.3-9.1 y). Older age, intravenous drug use, hepatitis C coinfection, lower baseline eGFR, female gender, lower CD4 count nadir, hypertension, diabetes, and cardiovascular disease (CVD) predicted CKD. The adjusted incidence rate ratios of these nine categorical variables were scaled and summed to create the risk score. The median risk score at baseline was -2 (interquartile range -4 to 2). There was a 1: 393 chance of developing CKD in the next 5 y in the low risk group (risk score = 5, 505 events), respectively. Number needed to harm (NNTH) at 5 y when starting unboosted atazanavir or lopinavir/ritonavir among those with a low risk score was 1,702 (95% CI 1,166-3,367); NNTH was 202 (95% CI 159-278) and 21 (95% CI 19-23), respectively, for those with a medium and high risk score. NNTH was 739 (95% CI 506-1462), 88 (95% CI 69-121), and 9 (95% CI 8-10) for those with a low, medium, and high risk score, respectively, starting tenofovir, atazanavir/ritonavir, or another boosted protease inhibitor. The Royal Free Hospital Clinic Cohort included 2,548 individuals, of whom 94 individuals developed CKD (3.7%) during 18,376 PYFU (median follow-up 7.4 y, range 0.3-12.7 y). Of 2,013 individuals included from the SMART/ESPRIT control arms, 32 individuals developed CKD (1.6%) during 8,452 PYFU (median follow-up 4.1 y, range 0.6-8.1 y). External validation showed that the risk score predicted well in these cohorts. Limitations of this study included limited data on race and no information on proteinuria. Conclusions Both traditional and HIV-related risk factors were predictive of CKD. These factors were used to develop a risk score for CKD in HIV infection, externally validated, that has direct clinical relevance for patients and clinicians to weigh the benefits of certain antiretrovirals against the risk of CKD and to identify those at greatest risk of CKD.Peer reviewe

John D. Rockefeller, Jr., a Portrait

Raymond B. Fosdick. John D. Rockefeller, Jr., a portrait “Mr. Fosdick has written a biography in its formal meaning — fully documented, chronologically precise — and not simply a personal tribute to a friend of more than forty years’ standing. The book, in consequence, is both biography and history, satisfying all the rigorous canons of personal and social analysis. It is to be read as part of the history of our time and as the record of a man of as much consequence to us as have been those other leaders and creators among his contemporaries who have affected public conduct. What we have here, then, is the narrative of a rich man who overcame the almost impossible handicaps of great wealth, limited religious upbringing, and a narrow and protective family circle. He might have become defensive and suspicious, or a recluse cultivating private and expensive hobbies, or a popular leader and therefore a demagogue (such patterns of the behavior of men of inherited fortunes are familiar throughout history), but instead he was able to grow and to assume great, national obligations. What might have been a puzzle slowly disappears under Mr. Fosdick’s skillful scholarship and his deep regard for his friend. The young Rockefeller (he is called throughout the book ‘JDR Jr.’), as early as 1910, when he was 36, severed his direct connections with business: did he do so because of a real or unconscious rejection of his father? Quite the contrary; father and son early forged strong bonds of mutual affection and respect, but while there never was hostility on the part of the son, neither was there subservience. JDR Jr. continued to support the philanthropies founded by the older man, the Rockefeller Institute for Medical Research, the General Education Board, and the Rockefeller Foundation, and to expand them; did he do this because he, like other men in public life — like Theodore Roosevelt, Woodrow Wilson, Louis D. Brandeis — was inevitably swept up in the ‘reform movement’ of the day? That was only a part, and possibly a minor one, of his development. For as his tastes became surer and his vocation clearer, he ranged wider and wider until his interests were as large as those of his country and his world. As one goes over the catalogue of his benefactions and interests — none ever representing a perfunctory concern, most requiring long years of careful planning with a devotion to exact detail that only the truly outstanding seem to possess — one grasps the sweep and boldness of JDR Jr.’s mind. Williamsburg; the Cloisters; Rockefeller Center; the Museum of Modern Art; the restoration of the Athenian Agora; Rheims, Versailles, Fontainebleau; Negro education; the four International Houses; Jackson Hole and the Jersey Palisades; the Library of the League of Nations at Geneva, and the site of the U.N. at New York; the interdenominational movement; the long battle to achieve industrial understanding in two decades marked by bitter strife between management and labor: this is only a partial list. Mr. Fosdick seeks the key to the Rockefellers in some observations made by Frederick T. Gates, that restless and fascinating man who had such a great influence on the lives of both father and son. In 1905, Gates wrote to the father: ‘Two courses are open to you. One is that you and your children while living should make final disposition of this great fortune in the form of permanent corporate philanthropies for the good of mankind... or at the close of a few lives now in being it must simply pass into the unknown, like some other great fortunes, with unmeasured and perhaps sinister possibilities.’ In 1929, Gates was satisfied, for he put down in a private document these remarks concerning JDR Jr.: ‘I have known no man who entered life more absolutely dominated by his sense of duty, more diligent in the quest of the right path, more eager to follow it at any sacrifice.’” — Louis M. Hacker, The New York Timeshttps://digitalcommons.rockefeller.edu/the-rockefellers/1038/thumbnail.jp